Goal: Our goal is to determine how tumor-specific replication abnormalities can be used to develop more effective anti-cancer therapies for adult acute myelogenous leukemia (AML) and glioblastoma multiforme (GBM), two rapidly lethal, treatment-refractory tumors. Our organizing hypothesis is that aberrant replication is common in AML and GBM, and represents an opportunity to improve treated survival by identifying drugs, small molecules and treatment regimens that synergize with replication defects to promote cell killing. Innovations: The Project 2 Research Plan has the following innovative features: ? Replication and replication abnormalities as tumor-specific therapeutic vulnerabilities in AML and GBM, a focus viewed as ?very novel? in prior review. ? DNA replication fork dynamics analyzed at the single molecule level. ? Network modeling to link replication abnormalities to genomic instability and therapeutic response. ? Microfluidic culture of GBM tissue on a novel platform to enable multiplexed drug profiling. ? Mixed-genotype competitive growth assays to determine mutant fitness?and thus potential therapeutic importance?in culture and in xenografts. Approach/Aims: We have three inter-related Aims collectively focused on defining DNA replication behavior and therapeutic response in AML, GSCs and GBM tissue.
Aim 1 : Define AML replication dynamics and the role of aberrant replication in therapeutic response.
Aim 2 : Define GBM replication dynamics and the role of aberrant replication in therapeutic response.
Aim 3 : Identify mutation-dependent mechanisms that drive subclonal heterogeneity and therapeutic resistance (a collaborative Project Aim). Impact: The proposed research will provide or develop: ? Detailed picture of mutation-dependent replication dynamics in AML and GBM. ? Link altered replication dynamics influence therapeutic response in AML and GBM. ? Identify or predict potentially effective new therapies and regimens for AML and GBM. ? Test potential new therapeutic vulnerabilities using clinically relevant preclinical models.

Public Health Relevance

PROJECT 2 ? Narrative Human tumor cells often display abnormalities in replication behavior. Project 2 will: 1) define replication dynamics in adult acute myelogenous leukemia (AML) and glioblastoma multiforme (GBM) cancer cells, in order to identify and characterize replication abnormalities; and 2) determine how replication abnormalities can be used to develop more effective anti-cancer therapies. We anticipate our results will be applicable to many additional human cancer types, and thus may be broadly useful in improving therapy for many cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA077852-16A1
Application #
8853658
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (J1))
Project Start
2000-03-07
Project End
2020-06-30
Budget Start
2015-07-08
Budget End
2016-06-30
Support Year
16
Fiscal Year
2015
Total Cost
$361,839
Indirect Cost
$127,639
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Orozco, Javier I J; Knijnenburg, Theo A; Manughian-Peter, Ayla O et al. (2018) Epigenetic profiling for the molecular classification of metastatic brain tumors. Nat Commun 9:4627
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Mikheev, Andrei M; Mikheeva, Svetlana A; Severs, Liza J et al. (2018) Targeting TWIST1 through loss of function inhibits tumorigenicity of human glioblastoma. Mol Oncol 12:1188-1202
Lee, Su-In; Celik, Safiye; Logsdon, Benjamin A et al. (2018) A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat Commun 9:42
Salk, Jesse J; Schmitt, Michael W; Loeb, Lawrence A (2018) Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet 19:269-285
Davis, Luther; Zhang, Yinbo; Maizels, Nancy (2018) Assaying Repair at DNA Nicks. Methods Enzymol 601:71-89
Yu, Ming; Heinzerling, Tai J; Grady, William M (2018) DNA Methylation Analysis Using Droplet Digital PCR. Methods Mol Biol 1768:363-383
Knijnenburg, Theo A; Wang, Linghua; Zimmermann, Michael T et al. (2018) Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23:239-254.e6
Kamath-Loeb, Ashwini S; Zavala-van Rankin, Diego G; Flores-Morales, Jeny et al. (2017) Homozygosity for the WRN Helicase-Inactivating Variant, R834C, does not confer a Werner syndrome clinical phenotype. Sci Rep 7:44081
Oshima, Junko; Sidorova, Julia M; Monnat Jr, Raymond J (2017) Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev 33:105-114

Showing the most recent 10 out of 137 publications